Research Analysts Issue Forecasts for SPRY FY2025 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ARS Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($1.20) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $30.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.58) per share.

SPRY has been the topic of a number of other research reports. Leerink Partners boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Raymond James lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $26.00.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $13.89 on Thursday. The company’s fifty day moving average is $12.45 and its two-hundred day moving average is $12.94. The firm has a market capitalization of $1.35 billion, a P/E ratio of -27.24 and a beta of 0.96. ARS Pharmaceuticals has a one year low of $6.13 and a one year high of $18.51.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SPRY. Rhumbline Advisers boosted its stake in shares of ARS Pharmaceuticals by 78.0% during the 2nd quarter. Rhumbline Advisers now owns 65,942 shares of the company’s stock worth $561,000 after purchasing an additional 28,888 shares during the last quarter. American Century Companies Inc. boosted its position in ARS Pharmaceuticals by 20.7% during the second quarter. American Century Companies Inc. now owns 97,803 shares of the company’s stock worth $832,000 after acquiring an additional 16,761 shares during the last quarter. Renaissance Technologies LLC grew its stake in ARS Pharmaceuticals by 884.9% in the 2nd quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock worth $1,056,000 after acquiring an additional 111,500 shares during the period. The Manufacturers Life Insurance Company acquired a new position in ARS Pharmaceuticals in the 2nd quarter valued at $180,000. Finally, Creative Planning lifted its stake in shares of ARS Pharmaceuticals by 7.0% during the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after purchasing an additional 2,307 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 14,772 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $13.75, for a total transaction of $203,115.00. Following the sale, the director now owns 210,346 shares in the company, valued at approximately $2,892,257.50. This represents a 6.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder James E. Flynn sold 528,456 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.04, for a total value of $9,533,346.24. Following the transaction, the insider now directly owns 5,274,735 shares of the company’s stock, valued at $95,156,219.40. The trade was a 9.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,095,558 shares of company stock valued at $16,853,686. Insiders own 40.10% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.